Production (Stage)
Lexicon Pharmaceuticals, Inc.
LXRX
$0.7667
$0.04976.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -95.25% | 1,417.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -95.25% | 1,417.37% | |||
| Cost of Revenue | -93.81% | 0.32% | |||
| Gross Profit | -155.07% | 102.58% | |||
| SG&A Expenses | -44.88% | -46.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -42.67% | -28.20% | |||
| Operating Income | -25.65% | 67.91% | |||
| Income Before Tax | 25.09% | 47.90% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 25.09% | 47.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 25.09% | 47.90% | |||
| EBIT | -25.65% | 67.91% | |||
| EBITDA | -25.56% | 68.05% | |||
| EPS Basic | 25.16% | 47.91% | |||
| Normalized Basic EPS | -17.79% | 66.90% | |||
| EPS Diluted | 25.16% | 47.91% | |||
| Normalized Diluted EPS | -17.79% | 66.90% | |||
| Average Basic Shares Outstanding | 0.16% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.16% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||